Fresenius Kabi – Recall of vecuronium injection

- On January 16, 2018, Fresenius Kabi announced a user level recall of one lot of vecuronium bromide 10 mg injection due to an out-of-specification (OOS) result for a compound at the 12 month stability test. The affected compound is an active metabolite of vecuronium bromide.

- The recalled lot was shipped from April 28, 2017 through May 11, 2017.

Product Description	NDC #	Lot # (expiration date)
Vecuronium bromide for injection, 10 mg per vial in a 10 ml vial	63323-781-10	ZG603 (10/2018)

- Vecuronium bromide is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

- The potential risk to patients due to the OOS stability test result is considered to be low. To date, Fresenius Kabi has not received any adverse event reports associated with the recalled product.

- Anyone with recalled product should immediately discontinue dispensing or distributing vials form the recalled lot and return all vials to Fresenius Kabi.

- Contact the Fresenius Kabi Quality Vigilance Department at **1-866-716-2459** for return information. For general questions regarding this recall, contact the Fresenius Kabi Vigilance/Medical Affairs Department at **1-800-551-7176**.